 |
 |
|
|
RESÚMENES AGOSTO 2006 |
Psychotic Disorders & Antipsychotics
(Haga un click en la información del journal
para acceder al resúmen)
Evidence That Early
Extrapyramidal Symptoms Predict Later Tardive
Dyskinesia: A Prospective Analysis of 10,000 Patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) Study
Diederik E. Tenback, Peter N. van Harten, Cees J. Slooff, Jim van Os, SOHO Study Group
American
Journal of Psychiatry 163:1438-1440, August 2006
Differential early onset of therapeutic response
with risperidone vs
conventional antipsychotics in patients with chronic
schizophrenia
Glick, Ira D; Shkedy, Ziv; Schreiner, Andreas
International Clinical Psychopharmacology.
21(5):261-266, September 2006
Drug-related movement disorders: training
experiences of psychiatrists
Kompanc Ariel Kuruvilla, José Antonio Sedano-Ruiz, Ann Ley
Psychiatric Bulletin (2006)
30: 300-303
Aripiprazole for schizophrenia.
Systematic review
H. G. El-Sayeh,
C. Morganti, C. E. Adams
The British Journal of Psychiatry (2006) 189:
102-108
Psychotic symptom and cannabis relapse in
recent-onset psychosis. Prospective study
L. Hides,
The British Journal of Psychiatry (2006) 189:
137-143
A Pilot, Open-Label Safety Study of Quetiapine for Treatment of Moderate Psychotic Agitation in
the Emergency Setting
CURRIER,
GLENN W;
Journal
of Psychiatric Practice. 12(4):223-228, July 2006
Energy expenditure and physical activity in clozapine use: implications for weight management
Jenny-Kay Sharpe, Terry J. Stedman, Nuala M. Byrne, Connie Wishart,
Andrew P. Hills
Australian and New Zealand Journal of Psychiatry.
Volume 40 Page 810 - September 2006
Ten-Year Recovery Outcomes for Clients With Co-Occurring Schizophrenia and Substance Use Disorders
Robert E. Drake, Gregory J. McHugo, Haiyi Xie,
Melinda Fox, Joan Packard and Barbara Helmstetter
Schizophrenia
Bulletin 2006 32(3):464-473
Morphological
correlates to cognitive dysfunction in schizophrenia as studied with Bayesian
regression
Glenn Lawyer, Hakan
Nyman, Ingrid Agartz, Stefan Arnborg,
Erik G Jonsson, Goran C Sedvall and Hakan Hall
BMC
Psychiatry
2006, 6:31;
10 August 2006
Four
symptom dimensions in outpatients with schizophrenia
Victòria Villalta-Gil, Miriam Vilaplana,
Susana Ochoa, Montserrat Dolz, Judith Usall, Josep Maria Haro, José Almenara, Juan Luis González, Carolina Lagares and
the NEDES Group
Comprehensive Psychiatry. Volume 47, Issue 5, September-October 2006, Pages 384-388
Optimisation
of long-term treatment in schizophrenia: Treating the true spectrum of symptoms
Siegfried Kasper
European Neuropsychopharmacology. Volume 16, Supplement 3, September 2006, Pages
S135-S141
Long-term health considerations in
schizophrenia: Metabolic effects and the role of abdominal adiposity
Luc F. Van Gaal
European
Neuropsychopharmacology. Volume 16,
Supplement 3, September 2006, Pages S142-S148
Differential metabolic effects of
antipsychotic treatments
Dan W. Haupt
European
Neuropsychopharmacology. Volume 16, Supplement 3,
September 2006, Pages S149-S155
Prevalence of Comorbid
Anxiety Disorders in Schizophrenia Spectrum Disorders: A Literature Review
Pokos, Vanda; Castle, David J
Current
Psychiatry Reviews, Volume 2, Number 3, August 2006, pp. 285-307(23)
Oestrogen-A Protective Factor in Schizophrenia?
Hafner, Heinz; Ehrenreich,
Hannelore; Gattaz,
Wagner F; Louza, Mario R; Riecher-Rossler, Anita; Kulkarni,
Jayashri
Current
Psychiatry Reviews, Volume 2, Number 3, August 2006, pp. 339-352(14)
A 1-Year Double-Blind Study of 2 Doses of
Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder
George
M. Simpson, Ramy A. Mahmoud,
Robert A. Lasser, Mary Kujawa,
Cynthia A. Bossie, Ibrahim Turkoz, Steven Rodriguez, and Georges M. Gharabawi
J Clin Psychiatry 2006;67:1194-1203
The Effect of Sudden Clozapine
Discontinuation on Management of Schizophrenic Patients: A Retrospective
Controlled Study
Chanoch Miodownik,
Vladimir Lerner, Adi Kibari,
Doron Toder, Hagit Cohen
J Clin Psychiatry 2006;67:1204-1208
Attenuation of Antipsychotic-Induced Weight
Gain With Early Behavioral Intervention in Drug-Naive
First-Episode Psychosis Patients: A Randomized Controlled Trial
Mario Álvarez-Jiménez, Cesar González-Blanch,
Jose Luis Vázquez-Barquero, Rocío
Pérez-Iglesias, Obdulia Martínez-García, Teresa Pérez-Pardal,
Mari Luz Ramírez-Bonilla, and Benedicto
Crespo-Facorro
J Clin Psychiatry 2006;67:1253-1260
Concomitant Medications May Not Improve
Outcome of Antipsychotic Monotherapy for Stabilized
Patients With Nonacute
Schizophrenia
Ira D.
Glick, Diana Pham, John M. Davis
J Clin Psychiatry 2006;67:1261-12
Estrogen,
Cognitive Function and Negative Symptoms in Female Schizophrenia
Young-Hoon Ko, Sook-Haeng
Joe, Woong Cho, Jeong-Hyun
Park, Jung-Jae Lee, In-Kwa Jung, Leen
Kim, Seung-Hyun Kim
Neuropsychobiology 2006;53:169-175
Long-term
patient monitoring for clozapine-induced agranulocytosis and neutropenia
in
Byung-Jo Kang, Man-Je
Cho, Jung-Tae Oh, Yanghyun Lee, Beang-Jin
Chae, Jaewook Ko
Human
Psychopharmacology: Clinical and Experimental. Volume 21,
Issue 6 , Pages 387 - 391
Plasma
concentrations of high-dose olanzapine in a
double-blind crossover study
Deanna
L. Kelly, Charles M. Richardson, Yang Yu, Robert R. Conley
Human
Psychopharmacology: Clinical and Experimental. Volume 21,
Issue 6, Pages 393 - 398
Long-term
treatment with long-acting risperidone in Korean
patients with schizophrenia
Moon-Soo Lee, Young-Hoon Ko, Sang-Hoon
Lee, Yong-Jin Seo, Seung-Hyun
Kim, Sook-Haeng Joe, Chang-Su Han, Jung-Ho Lee, In-Kwa Jung
Human
Psychopharmacology: Clinical and Experimental. Volume 21,
Issue 6, Pages 399 - 407
Health Status of Individuals With Serious Mental Illness
Faith B. Dickerson, Clayton H.
Brown, Gail L. Daumit, Fang LiJuan,
Richard W. Goldberg, Karen Wohlheiter and Lisa B.
Dixon
Schizophrenia
Bulletin 2006 32(3):584-589
Has Schizophrenia Evolved Into Less Serious
Illness?
Mark Moran
Psychiatr News August 18, 2006;
Volume 41, Number 16, page 21
Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial
Richard S E Keefe, Robert M Bilder,
Philip D Harvey, Sonia M Davis, Barton W Palmer, James
M Gold, Herbert Y Meltzer, Michael F Green, Del D Miller,
Jose M Canive, Lawrence W Adler, Theo
C Manschreck, Marvin Swartz, Robert Rosenheck, Diana O Perkins, Trina M Walker, T
Scott Stroup, Joseph P McEvoy and Jeffrey
A Lieberman
Neuropsychopharmacology (2006) 31, 2033–2046
Low
rates of treatment for hypertension, dyslipidemia and
diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at
baseline
Henry A. Nasrallah,
Jonathan M. Meyer, Donald C. Goff, Joseph P. McEvoy,
Sonia M. Davis, T. Scott Stroup and Jeffrey A. Lieberman
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 15-22
Higher
fasting serum insulin levels are associated with a better psychopathology
profile in acutely ill non-diabetic inpatients with schizophrenia
Xiaoduo Fan, Emily Liu,
Cynthia Pristach, Donald C. Goff and David C.
Henderson
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 30-35
Insight
and frontal cortical function in schizophrenia: A review
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 54-70
Diagnostic
stability over one year in first-episode psychosis
Jean Addington, Ana Chaves
and Donald Addington
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 71-75
Differential
trends in prevalence of diabetes and unrelated general medical illness for
schizophrenia patients before and after the atypical antipsychotic era
Anirban Basu and Herbert Y. Meltzer
Schizophrenia Research. Volume
86, Issues 1-3, September 2006, Pages 99-109
Antipsychotic medication and cognitive function in
schizophrenia
Hiroaki Hori, Hiroko Noguchi, Ryota Hashimoto,
Tetsuo Nakabayashi, Mayu Omori, Sho Takahashi, Ryotaro Tsukue, Kimitaka Anami,
Naotsugu Hirabayashi, Seiichi Harada, Osamu Saitoh, Masao Iwase, Osami
Kajimoto, Masatoshi Takeda, Shigeo Okabe and Hiroshi Kunugi
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 138-146
Are
there subtypes of suicidal schizophrenia? A prospective study
Francisco J. Acosta, Eduardo J. Aguilar, María R. Cejas, Ramón Gracia, Araceli Caballero-Hidalgo
and Samuel G. Siris
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 215-220
Suicidality in first episode psychosis
Mary Clarke, Peter Whitty,
Stephen Browne, Orfhlaith Mc Tigue,
Anthony Kinsella, John L. Waddington, Conall Larkin and Eadbhard
O'Callaghan
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 221-225
Depressive
symptom patterns in patients with chronic schizophrenia and subsyndromal
depression
Sidney Zisook, Maren Nyer, John Kasckow, Shah Golshan, David Lehmanand Lori Montross
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 226-233
Olanzapine and haloperidol in first episode psychosis:
Two-year data
A.I. Green, J.A. Lieberman, R.M. Hamer,
I.D. Glick, R.E. Gur, R.S. Kahn, J.P. McEvoy, D.O. Perkins, A.J. Rothschild, T. Sharma, M.F. Tohen, S. Woolson, R.B. Zipursky and The HGDH Study Group
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 234-243
Sexual
dysfunction associated with second-generation antipsychotics
in outpatients with schizophrenia or schizoaffective disorder: An empirical
evaluation of olanzapine, risperidone,
and quetiapine
Matthew J. Byerly, Paul A.
Nakonezny, Brianne Magouirk
Bettcher, Thomas Carmody,
Robert Fisher and A. John Rush
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 244-250
Comorbid substance-use in schizophrenia: Relation to positive and
negative symptoms
A. Talamo, F. Centorrino, L. Tondo, A. Dimitri,
J. Hennen and R.J. Baldessarini
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 251-255
Does
smoking reduce akathisia? Testing a narrow version of
the self-medication hypothesis
Jose de Leon, Francisco J. Diaz, M.Carmen
Aguilar, Dolores Jurado and Manuel Gurpegu
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 256-268
Increased
caffeine and nicotine consumption in community-dwelling patients with
schizophrenia
Martin Strassnig, Jaspreet S. Brar and Rohan Ganguli
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 269-275
Fewer
but heavier caffeine consumers in schizophrenia: A case-control study
Manuel Gurpegui, M. Carmen
Aguilar, José M. Martínez-Ortega, Dolores Jurado, Francisco J. Diaz, Hernando M. Quintana and Jose de
Leon
Schizophrenia Research. Volume 86, Issues 1-3, September 2006, Pages 276-283
Serum
creatine kinase levels in
chronic psychosis patients − a comparison between atypical and
conventional antipsychotics
Kristina Melkersson
Neuroleptic
drugs in the human brain. Clinical impact of persistence and region-specific
distribution
Johannes Kornhuber, Jens Wiltfang, Peter Riederer and
Stefan Bleich
Impairment of theory of mind in patients in
remission following first episode of schizophrenia
Y. Inoue,
K. Yamada, M. Hirano, M. Shinohara, T. Tamaoki,
H. Iguchi, Y. Tonooka and S. Kanba
Comparative study of neuropsychological
correlates in schizophrenia with onset in childhood, adolescence and adulthood
Parthasarathy Biswas,
Savita Malhotra,
Anil Malhotra and Nitin Gupta
European Child & Adolescent Psychiatry. Volume 15, Number 6 / September, 2006: 360-366
The Metabolic Effects of Antipsychotic
Medications
Can J Psychiatry 2006;51:480–491
Metabolic Monitoring for Patients Treated
With Antipsychotic Medications
Can J Psychiatry 2006;51:492–501
Long-Acting Injectable
Risperidone Compared With Zuclopenthixol
in the Treatment of Schizophrenia With Substance Abuse
Comorbidity